iBio, Inc. - Product Pipeline Review - 2016

  • ID: 3846540
  • Company Profile
  • 47 pages
  • Global Markets Direct
  • iBio Inc
1 of 4
iBio, Inc. - Product Pipeline Review - 2016

Summary

‘iBio, Inc. - Product Pipeline Review - 2016’, provides an overview of the iBio, Inc.’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by iBio, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the pipeline therapeutic landscape of iBio, Inc.
- The report provides overview of iBio, Inc. including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses iBio, Inc.’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features iBio, Inc.’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

- Evaluate iBio, Inc.’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for iBio, Inc.
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding iBio, Inc.’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 4
List of Tables

List of Figures

iBio, Inc. Snapshot

iBio, Inc. Overview

Key Information

Key Facts

iBio, Inc. - Research and Development Overview

Key Therapeutic Areas

iBio, Inc. - Pipeline Review

Pipeline Products by Stage of Development

Pipeline Products - Monotherapy

Pipeline Products - Combination Treatment Modalities

iBio, Inc. - Pipeline Products Glance

iBio, Inc. - Clinical Stage Pipeline Products

Phase I Products/Combination Treatment Modalities

iBio, Inc. - Early Stage Pipeline Products

Preclinical Products/Combination Treatment Modalities

Discovery Products/Combination Treatment Modalities

iBio, Inc. - Drug Profiles

anthrax vaccine

Product Description

Mechanism of Action

R&D Progress

HAI-05

Product Description

Mechanism of Action

R&D Progress

influenza [strain A/H1N1] vaccine

Product Description

Mechanism of Action

R&D Progress

malaria vaccine

Product Description

Mechanism of Action

R&D Progress

NaAPR1M-74

Product Description

Mechanism of Action

R&D Progress

anthrax + plague vaccine

Product Description

Mechanism of Action

R&D Progress

human papillomavirus [Serotype 16] vaccine

Product Description

Mechanism of Action

R&D Progress

IBIOCFB-03

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody for Anthrax

Product Description

Mechanism of Action

R&D Progress

Monoclonal Antibody to Inhibit Neuraminidase for Influenza

Product Description

Mechanism of Action

R&D Progress

palivizumab biosimilar

Product Description

Mechanism of Action

R&D Progress

Recombinant Protein to Inhibit C1-esterase for Hereditary Angioedema

Product Description

Mechanism of Action

R&D Progress

yellow fever vaccine

Product Description

Mechanism of Action

R&D Progress

influenza [strain A/H7N9] vaccine

Product Description

Mechanism of Action

R&D Progress

Recombinant Protein for Oncology

Product Description

Mechanism of Action

R&D Progress

trypanosomiasis vaccine

Product Description

Mechanism of Action

R&D Progress

iBio, Inc. - Pipeline Analysis

iBio, Inc. - Pipeline Products by Target

iBio, Inc. - Pipeline Products by Route of Administration

iBio, Inc. - Pipeline Products by Molecule Type

iBio, Inc. - Pipeline Products by Mechanism of Action

iBio, Inc. - Recent Pipeline Updates

iBio, Inc. - Dormant Projects

iBio, Inc. - Locations And Subsidiaries

Head Office

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

iBio, Inc., Key Information

iBio, Inc., Key Facts

iBio, Inc. - Pipeline by Indication, 2016

iBio, Inc. - Pipeline by Stage of Development, 2016

iBio, Inc. - Monotherapy Products in Pipeline, 2016

iBio, Inc. - Combination Treatment Modalities in Pipeline, 2016

iBio, Inc. - Phase I, 2016

iBio, Inc. - Preclinical, 2016

iBio, Inc. - Discovery, 2016

iBio, Inc. - Pipeline by Target, 2016

iBio, Inc. - Pipeline by Route of Administration, 2016

iBio, Inc. - Pipeline by Molecule Type, 2016

iBio, Inc. - Pipeline Products by Mechanism of Action, 2016

iBio, Inc. - Recent Pipeline Updates, 2016

iBio, Inc. - Dormant Developmental Projects,2016 44List of Figures

iBio, Inc. - Pipeline by Top 10 Indication, 2016

iBio, Inc. - Pipeline by Stage of Development, 2016

iBio, Inc. - Monotherapy Products in Pipeline, 2016

iBio, Inc. - Pipeline by Target, 2016

iBio, Inc. - Pipeline by Route of Administration, 2016

iBio, Inc. - Pipeline by Molecule Type, 2016

iBio, Inc. - Pipeline Products by Mechanism of Action, 2016
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll